



Contents lists available at [ScienceDirect](http://www.sciencedirect.com)

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl



Corrigendum

Corrigendum to “Novel benzimidazole derivatives as selective CB2 agonists” [*Bioorg. Med. Chem. Lett.* 18 (2008) 3695–3700]

Daniel Pagé^{a,*}, Elise Balaux^a, Luc Boisvert^a, Ziping Liu^a, Claire Milburn^a, Maxime Tremblay^a, Zhongyong Wei^a, Simon Woo^a, Xuehong Luo^a, Yun-Xing Cheng^a, Hua Yang^a, Sanjay Srivastava^a, Fei Zhou^a, William Brown^a, Mirosław Tomaszewski^a, Christopher Walpole^a, Leila Hodzic^b, Stéphane St-Onge^b, Claude Godbout^b, Dominic Salois^b, Kemal Payza^b

^a Department of Medicinal Chemistry, AstraZeneca R&D Montréal, 7171 Frederick-Banting, St-Laurent, Que., Canada H4S 1Z9

^b Department of Molecular Pharmacology, AstraZeneca R&D Montréal, 7171 Frederick-Banting, St-Laurent, Que., Canada H4S 1Z9

The name of Kemal Payza mistakenly appeared as Keymal Payza in the author line. The correct author line appears above.

DOI of original article: [10.1016/j.bmcl.2008.05.073](https://doi.org/10.1016/j.bmcl.2008.05.073)

* Corresponding author. Tel.: +1 514 832 3200; fax: +1 514 832 3232.

E-mail address: daniel.page@astrazeneca.com (D. Pagé).